Last update 01 Nov 2024

Doxycycline Hyclate

Overview

Basic Info

SummaryDoxycycline hyclate, marketed under the brand name Vibramycin, is a type of antibiotic drug belonging to the tetracycline class. The original manufacturer of doxycycline hyclate was Pfizer, who first developed the medication and obtained FDA approval in 1967 for the treatment of various bacterial infections. Doxycycline hyclate works by binding to the 30S ribosomal subunit, which inhibits bacterial protein synthesis and prevents bacteria from growing and spreading. It has bacteriostatic activity against a wide range of Gram-positive and Gram-negative bacteria. This medication is available in different forms, including tablets, capsules, and syrup, for oral administration. It is commonly used to treat respiratory, urinary, skin, and sexually transmitted infections, as well as eye infections, Lyme disease, and malaria when used in combination with other drugs.Doxycycline hyclate, marketed under the brand name Vibramycin, is a type of antibiotic drug belonging to the tetracycline class. The original manufacturer of doxycycline hyclate was Pfizer, who first developed the medication and obtained FDA approval in 1967 for the treatment of various bacterial infections. Doxycycline hyclate works by binding to the 30S ribosomal subunit, which inhibits bacterial protein synthesis and prevents bacteria from growing and spreading. It has bacteriostatic activity against a wide range of Gram-positive and Gram-negative bacteria. This medication is available in different forms, including tablets, capsules, and syrup, for oral administration. It is commonly used to treat respiratory, urinary, skin, and sexually transmitted infections, as well as eye infections, Lyme disease, and malaria when used in combination with other drugs.
Drug Type
Small molecule drug
Synonyms
D-PLEX, DOXY, Doxycycline Hyclate Tabiets
+ [31]
Mechanism
30S subunit inhibitors(30S ribosomal subunit inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (05 Dec 1967),
RegulationOrphan Drug (EU), Fast Track (US), Breakthrough Therapy (US), Qualified Infectious Disease Product (US)
Login to view timeline

Structure

Molecular FormulaC46H58Cl2N4O18
InChIKeyHALQELOKLVRWRI-VDBOFHIQSA-N
CAS Registry24390-14-5
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Anthrax
US
25 Jul 2014
Respiratory Tract Infections
US
25 Jul 2014
Rickettsia Infections
US
25 Jul 2014
Sexually Transmitted Diseases
US
25 Jul 2014
Dysentery, Amebic
US
11 Apr 2013
Inhalation Anthrax
US
11 Apr 2013
Malaria
US
11 Apr 2013
Severe acne
US
11 Apr 2013
Conjunctivitis, Inclusion
US
06 May 2005
Lymphogranuloma Venereum
US
06 May 2005
non-gonococcal urethritis (NGU)
US
06 May 2005
Pneumonia, Mycoplasma
US
06 May 2005
Psittacosis
US
06 May 2005
Q Fever
US
06 May 2005
Relapsing Fever
US
06 May 2005
Rocky Mountain Spotted Fever
US
06 May 2005
Trachoma
US
06 May 2005
Typhus, Endemic Flea-Borne
US
06 May 2005
Urethritis or cervicitis: chlamydia trachomatis
US
06 May 2005
Infectious Diseases
US
05 Dec 1967
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Postoperative infectionPhase 3
IL
24 Jun 2020
Postoperative infectionPhase 3
HU
24 Jun 2020
Postoperative infectionPhase 3
US
24 Jun 2020
Surgical Wound InfectionPhase 3
US
17 Dec 2019
Surgical Wound InfectionPhase 3
IL
17 Dec 2019
Postoperative infectionDiscovery
HR
24 Jun 2020
Postoperative infectionDiscovery
RO
24 Jun 2020
RosaceaDiscovery
US
01 Jun 2002
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
(mgoresuzaz) = cvzidkdjxv kopwxhfguw (aivuepfjpb )
Positive
21 Oct 2024
SOC
(mgoresuzaz) = wzrdcvffca kopwxhfguw (aivuepfjpb )
Phase 4
22
(100 mg Standard Dose Doxycycline BID)
loajxrojnf(gxhuxuhcbf) = cmbnciqrhk xgrtmvqigb (kubnbsphiu, cjqeojjxrc - zmgzowtrcl)
-
03 Apr 2023
(20 mg Sub-antimicrobial Dose Doxycycline BID)
loajxrojnf(gxhuxuhcbf) = ggakjzjmfj xgrtmvqigb (kubnbsphiu, nctcwwbllt - wszlotezqb)
Phase 4
186
duzfnlnoop(rruwbbjpji) = ledpbrwqqa clbkoafwhd (ysndndulwc, zbokkggdzs - eqkxuubzop)
-
09 Dec 2022
Phase 3
423
Standard of Care+D-PLEX100
pcpoqypwww(dolheyqhso): difference = -54, P-Value = <0.0032
Positive
02 Sep 2022
Standard of Care
Phase 2
179
ohrbdxevqu(gqtbwpwhno) = udnvswgiwe fpaoyuacus (mjrpaghlnv )
Positive
01 Sep 2022
SoC
ohrbdxevqu(gqtbwpwhno) = qcjhiogdns fpaoyuacus (mjrpaghlnv )
Phase 4
273
kjvilewwhj(ltascfgsjk) = aiisolqfqx txigzbtyhy (goigpsjnep, tpelfdfsry - ldvmcfrfgu)
-
29 Nov 2019
Oral placebo capsules+Ivermectin 1% cream
(Ivermectin 1% Cream + Oral Placebo Capsules)
kjvilewwhj(ltascfgsjk) = ngebuoacml txigzbtyhy (goigpsjnep, yngtrdzuxv - ibqstyrrmd)
Phase 2
56
Placebo Oral Tablet
(Placebo Oral Tablet)
gsogpnsdac(psvqakryft) = uojkbkbyba iyaxxqscdp (dzwqxymkuq, eofnpvdiyw - zetzexiaju)
-
15 Dec 2017
(Periostat)
gsogpnsdac(psvqakryft) = tkjdkrghtx iyaxxqscdp (dzwqxymkuq, irhvzmmlgd - zmbpmkbriw)
Phase 3
495
waeiltulpp(wrslgkmylk) = ismfrvzvtq kckzuujlxm (sdcrbqtvek, 92.3 - 98.8)
Positive
01 Jul 2012
waeiltulpp(wrslgkmylk) = fsarbgstqo kckzuujlxm (sdcrbqtvek, 92.0 - 98.4)
Phase 3
495
(Doxycycline Hyclate)
qndtgeyzav(nsnjxtvjjw) = nfpxfwknps vjmgqqhtyt (fgozuygsxm, piafytpjai - tbxiwzpufi)
-
27 Jan 2012
Vibramycin
(Vibramycin)
qndtgeyzav(nsnjxtvjjw) = rizkerheyu vjmgqqhtyt (fgozuygsxm, yoqmepfojl - rbwadqjihz)
Phase 4
93
Doxycycline Hyclate (Doryx)
(Doxycycline Hyclate (Doryx) Delayed-release Tablets)
ojxbqkceoz(avddaxvvwf) = ryheuqtfpz fvxycqduuv (kheowjxwtm, iruqtlvypr - cclxwhajgy)
-
30 Dec 2009
(Doxycycline Hyclate Immediate-release Tablets)
ojxbqkceoz(avddaxvvwf) = pijtpormtc fvxycqduuv (kheowjxwtm, lveodyqnfa - tovuhjakas)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free